TY  - JOUR 
AU  - Steg, P. G.
AU  - Szarek, M.
AU  - Bhatt, D. L.
AU  - Bittner, V. A.
AU  - Bregeault, M. F.
AU  - Dalby, A. J.
AU  - Diaz, R.
AU  - Edelberg, J. M.
AU  - Goodman, S. G.
AU  - Hanotin, C.
AU  - Harrington, R. A.
AU  - Jukema, J. W.
AU  - Lecorps, G.
AU  - Mahaffey, K. W.
AU  - Moryusef, A.
AU  - Ostadal, P.
AU  - Parkhomenko, A.
AU  - Pordy, R.
AU  - Roe, M. T.
AU  - Tricoci, P.
AU  - Vogel, R.
AU  - White, H. D.
AU  - Zeiher, A. M.
AU  - Schwartz, G. G.
AU  - Iñiguez Romo, Andres
AU  - González Juanatey, José Ramón
AU  - González Juanatey, Carlos
PY  - 2019
SN  - 0009-7322
UR  - http://hdl.handle.net/20.500.11940/15752
AB  - BACKGROUND: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary...
LA  - eng
KW  - Injections
KW  - Hypercholesterolemia
KW  - Drug Therapy
KW  - Middle Aged
KW  - Humans
KW  - Antibodies
KW  - Treatment Outcome
KW  - Cholesterol
KW  - Hydroxymethylglutaryl-CoA Reductase Inhibitors
KW  - Follow-Up Studies
KW  - Acute Coronary Syndrome
KW  - Aged
KW  - Double-Blind Method
TI  - Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial
DO  - 10.1161/circulationaha.118.038840
T2  - Circulation
M2  - 103
KW  - CHUS
KW  - CHUVI
KW  - HULA
VL  - 140
ER  -